Longevity announces continued Nasdaq listing to complete 20/20 BioLabs deal

Longevity Health (XAGE) announced that it has received a favorable decision from the Nasdaq Hearings Panel granting the company’s request to continue its listing on Nasdaq subject to the satisfaction of the Nasdaq initial listing rules for the combined company following the proposed merger with 20/20 BioLabs on or before September 2. This decision follows the panel’s review of the company’s recent business developments, financial disclosures, and proposed merger with 20/20. As part of its strategic plan, Longevity presented its intention to merge with 20/20 and effect a 1-for-30 reverse stock split to address Nasdaq’s listing requirements. The company filed the S-4 registration statement for the proposed merger on May 8 and effected the reverse stock split on May 12.